|
1
|
Imamura H, Matsuyama Y, Tanaka E, et al:
Risk factors contributing to early and late phase intrahepatic
recurrence of hepatocellular carcinoma after hepatectomy. J
Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhong C, Guo RP, Li JQ, et al: A
randomized controlled trial of hepatectomy with adjuvant
transcatheter arterial chemoembolization versus hepatectomy alone
for stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol.
135:1437–1445. 2009. View Article : Google Scholar
|
|
3
|
Capussotti L, Muratore A, Amisano M, et
al: Liver resection for hepatocellular carcinoma on cirrhosis:
analysis of mortality, morbidity and survival - a European single
center experience. Eur J Surg Oncol. 31:986–993. 2005. View Article : Google Scholar
|
|
4
|
Lang H, Sotiropoulos GC, Brokalaki EI, et
al: Survival and recurrence rates after resection for
hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg.
205:27–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhong JH, Li H, Li LQ, et al: Adjuvant
therapy options following curative treatment of hepatocellular
carcinoma: a systematic review of randomized trials. Eur J Surg
Oncol. 38:286–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhong JH and Li LQ: Postoperative adjuvant
transarterial chemoembolization for participants with
hepatocellular carcinoma: a meta-analysis. Hepatol Res. 40:943–953.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhong JH, Ma L, Wu LC, et al: Adoptive
immunotherapy for postoperative hepatocellular carcinoma: a
systematic review. Int J Clin Pract. 66:21–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Ruff P, Tassopoulos N, et al: A
phase II trial of oral eniluracil/5-fluorouracil in patients with
inoperable hepatocellular carcinoma. Eur J Cancer. 37:1352–1358.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Benson AB III, Mitchell E, Abramson N,
Klencke B, Ritch P, Burnhan JP, McGuirt C, Bonny T, Levin J and
Hohneker J: Oral eniluracil/5-fluorouracil in patients with
inoperable hepatocellular carcinoma. Ann Oncol. 13:576–581. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson PJ: Hepatocellular carcinoma: is
current therapy really altering outcome? Gut. 51:459–462. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moher D, Cook DJ, Eastwood S, et al:
Improving the quality of reports of meta-analyses of randomised
controlled trials: the QUOROM statement. QUOROM Group. Br J Surg.
87:1448–1454. 2000. View Article : Google Scholar
|
|
12
|
Xia Y, Qiu Y, Li J, et al: Adjuvant
therapy with capecitabine postpones recurrence of hepatocellular
carcinoma after curative resection: a randomized controlled trial.
Ann Surg Oncol. 17:3137–3144. 2010. View Article : Google Scholar
|
|
13
|
Hasegawa K, Takayama T, Ijichi M, et al:
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a
randomized trial. Hepatology. 44:891–895. 2006. View Article : Google Scholar
|
|
14
|
Yamamoto M, Arii S, Sugahara K and Tobe T:
Adjuvant oral chemotherapy to prevent recurrence after curative
resection for hepatocellular carcinoma. Br J Surg. 83:336–340.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ono T, Nagasue N, Kohno H, et al: Adjuvant
chemotherapy with epirubicin and carmofur after radical resection
of hepatocellular carcinoma: a prospective randomized study. Semin
Oncol. 24(Suppl 6): 18–25. 1997.PubMed/NCBI
|
|
16
|
Kohno H, Nagasue N, Hayashi T, et al:
Postoperative adjuvant chemotherapy after radical hepatic resection
for hepatocellular carcinoma (HCC). Hepatogastroenterology.
43:1405–1409. 1996.PubMed/NCBI
|
|
17
|
Takenaka K, Yoshida K, Nishizaki T, et al:
Postoperative prophylactic lipiodolization reduces the intrahepatic
recurrence of hepatocellular carcinoma. Am J Surg. 169:400–405.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patt YZ, Hassan MM, Aguayo A, et al: Oral
capecitabine for the treatment of hepatocellular carcinoma,
cholangiocarcinoma, and gallbladder carcinoma. Cancer. 101:578–586.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edeline J, Raoul JL, Vauleon E, et al:
Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic
liver: a retrospective study. World J Gastroenterol. 15:713–716.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu AX: Systemic treatment of
hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol.
17:1247–1256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uchino K, Obi S, Tateishi R, et al:
Systemic combination therapy of intravenous continuous
5-fluorouracil and subcutaneous pegylated interferon alfa-2a for
advanced hepatocellular carcinoma. J Gastroenterol. 47:1152–1159.
2012. View Article : Google Scholar
|
|
22
|
Cao H, Phan H and Yang LX: Improved
chemotherapy for hepatocellular carcinoma. Anticancer Res.
32:1379–1386. 2012.
|
|
23
|
Ono T, Yamanoi A, Nazmy El Assal O, et al:
Adjuvant chemotherapy after resection of hepatocellular carcinoma
causes deterioration of long-term prognosis in cirrhotic patients:
metaanalysis of three randomized controlled trials. Cancer.
91:2378–2385. 2001. View Article : Google Scholar
|
|
24
|
Davis AJ and Tannock JF: Repopulation of
tumour cells between cycles of chemotherapy: a neglected factor.
Lancet Oncol. 1:86–93. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai EC, Lo CM, Fan ST, et al:
Postoperative adjuvant chemotherapy after curative resection of
hepatocellular carcinoma: a randomized controlled trial. Arch Surg.
133:183–188. 1998.PubMed/NCBI
|
|
26
|
Abou-Alfa GK, Johnson P, Knox JJ, et al:
Doxorubicin plus sorafenib vs. doxorubicin alone in patients with
advanced hepatocellular carcinoma: a randomized trial. JAMA.
304:2154–2160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng AL, Kang YK, Chen Z, et al: Efficacy
and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar : PubMed/NCBI
|
